dapagliflozin

• heart failure-related rehospitalization

  decreases, RR = 0.53, 95% CI [0.30, 0.91], P < 0.05

  It also reduced major adverse cardiovascular events (RR = 0.33, 95% CI [0.18, 0.60], P < 0.05), and heart failure-related rehospitalization (RR = 0.53, 95% CI [0.30, 0.91], P < 0.05).

  PMID:40535333 · both readings recorded this

• major adverse cardiovascular events (MACE)

  decreases, RR = 0.33, 95% CI [0.18, 0.60]

  It also reduced major adverse cardiovascular events (RR = 0.33, 95% CI [0.18, 0.60], P < 0.05), and heart failure-related rehospitalization (RR = 0.53, 95% CI [0.30, 0.91], P < 0.05).

  PMID:40535333 · one of two readings recorded this

• major adverse cardiovascular events

  decreases, RR = 0.33, 95% CI [0.18, 0.60], P < 0.05

  It also reduced major adverse cardiovascular events (RR = 0.33, 95% CI [0.18, 0.60], P < 0.05), and heart failure-related rehospitalization (RR = 0.53, 95% CI [0.30, 0.91], P < 0.05).

  PMID:40535333 · both readings recorded this

• adverse event rate

  no effect, OR: 0.37; 95% CI: 0.07-2.03, p = 0.25

  There was no significant increase in adverse events (OR: 0.37; 95% CI: 0.07-2.03; P=0.25).

  PMID:40612436 · both readings recorded this

• fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG) and HbA1c

  decreases, FPG MD -1.19 mmol/L [-1.40, -0.98]; 2hPG MD -1.36 mmol/L [-1.44, -1.27]; HbA1c MD -0.87% [-1.04, -0.71]

  Glycemic control also improved, with reductions in FPG (MD, 95% CI: -1.19 mmol/L [-1.40, -0.98]; P<0.01), 2hPG (MD, 95% CI: -1.36 mmol/L[-1.44, -1.27]; P<0.01), and HbA1c levels (MD, 95% CI: -0.87% [-1.04, -0.71]; P<0.01).

  PMID:40612436 · one of two readings recorded this

• fasting plasma glucose (FPG)

  decreases, MD -1.19 mmol/L [-1.40, -0.98]

  Glycemic control also improved, with reductions in FPG (MD, 95% CI: -1.19 mmol/L [-1.40, -0.98]; P<0.01), 2hPG (MD, 95% CI: -1.36 mmol/L[-1.44, -1.27]; P<0.01), and HbA1c levels (MD, 95% CI: -0.87% [-1.04, -0.71]; P<0.01).

  PMID:40612436 · one of two readings recorded this

• HbA1c

  decreases, MD -0.87% [-1.04, -0.71]

  Glycemic control also improved, with reductions in FPG (MD, 95% CI: -1.19 mmol/L [-1.40, -0.98]; P<0.01), 2hPG (MD, 95% CI: -1.36 mmol/L[-1.44, -1.27]; P<0.01), and HbA1c levels (MD, 95% CI: -0.87% [-1.04, -0.71]; P<0.01).

  PMID:40612436 · one of two readings recorded this

• HbA1c level

  decreases, pooled SMD −0.56; 95% CI [−1.08, −0.04], p = 0.03

  Not recorded as a finding: the comparison was against another active treatment

  The analysis reported significant decrease in HbA1c level in the dapagliflozin treated group compared to controls (pooled SMD −0.56; 95% CI [−1.08, −0.04]; P overall effect =.03).

  PMID:40629621 · one of two readings recorded this

• HbA1c level

  decreases, pooled SMD -0.56; 95% CI [-1.08, -0.04], p = 0.03, n = 296

  The analysis reported significant decrease in HbA1c level in the dapagliflozin treated group compared to controls (pooled SMD −0.56; 95% CI [−1.08, −0.04]; P overall effect =.03).

  PMID:40629621 · one of two readings recorded this

• HbA1c, serum creatinine and urine albumin-to-creatinine ratio (pooled standardized mean difference), and hypoglycemia incidence (risk ratio)

  decreases, pooled SMD -0.56 (95% CI -1.08, -0.04), p = 0.03, n = 296

  Not recorded as a finding: the comparison was against another active treatment

  The analysis reported significant decrease in HbA1c level in the dapagliflozin treated group compared to controls (pooled SMD −0.56; 95% CI [−1.08, −0.04]; P overall effect =.03).

  PMID:40629621 · one of two readings recorded this

• hypoglycemia incidence

  decreases, pooled RR 0.26; 95% CI [0.08, 0.82], p = 0.02, n = 296

  The analysis reported significant incidence of hypoglycemia events in the dapagliflozin treated group compared to controls (pooled RR 0.26; 95% CI [0.08, 0.82]; P overall effect =.02).

  PMID:40629621 · both readings recorded this

• serum creatinine level

  decreases, pooled SMD -0.84; 95% CI [-1.07, -0.61], n = 296

  There was significant decrease in serum creatinine level in experimental group compared to controls (pooled SMD −0.84; 95% CI [−1.07, −0.61]; P overall effect <.00001).

  PMID:40629621 · both readings recorded this

• urine albumin-to-creatinine ratio (UACR)

  no effect, pooled SMD −1.45; 95% CI [−3.33, 0.42]; P overall effect =.13, p = 0.13

  There was insignificant change in UACR in dapagliflozin treated group compared to controls (pooled SMD −1.45; 95% CI [−3.33, 0.42]; P overall effect =.13).

  PMID:40629621 · both readings recorded this

• all-cause death

  HR, 0.66 (95% CI, 0.43-1.00)

  Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48-1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43-1.00]).

  PMID:40884036 · one of two readings recorded this

• cardiovascular death and all-cause death

  no effect, cardiovascular death HR, 0.78 [95% CI, 0.48-1.27]; all-cause death HR, 0.66 [95% CI, 0.43-1.00]

  Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48-1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43-1.00]).

  PMID:40884036 · one of two readings recorded this

• cardiovascular death or worsening heart failure, and all-cause death (meta-analysis of SGLT2 inhibitor class trials, not dapagliflozin specifically)

  decreases, CV death or worsening HF HR, 0.71 [95% CI, 0.54-0.93] P=0.012; all-cause death HR, 0.57 [95% CI, 0.41-0.80]; P=0.001, p = 0.012

  In a meta-analysis of patients hospitalized for HF, SGLT2 inhibitors reduced the early risk of cardiovascular death or worsening HF (HR, 0.71 [95% CI, 0.54-0.93] P=0.012) and of all-cause death (HR, 0.57 [95% CI, 0.41-0.80]; P=0.001).

  PMID:40884036 · one of two readings recorded this

• cardiovascular death

  HR, 0.78 (95% CI, 0.48-1.27)

  Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48-1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43-1.00]).

  PMID:40884036 · one of two readings recorded this

• composite of cardiovascular death or worsening heart failure through 2 months

  HR 0.86 (95% CI, 0.68-1.08), p = 0.2

  The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68-1.08]; P=0.20).

  PMID:40884036 · both readings recorded this

• composite of time to cardiovascular death or worsening heart failure through 2 months, hazard ratio

  HR 0.86 (95% CI, 0.68-1.08), p = 0.2

  Not recorded as a finding: this platform holds no node for the endpoint

  The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68-1.08]; P=0.20).

  PMID:40884036 · one of two readings recorded this

• composite of time to cardiovascular death or worsening heart failure through 2 months

  no effect, hazard ratio [HR], 0.86 [95% CI, 0.68-1.08]; P=0.20, p = 0.2

  Not recorded as a finding: this platform holds no node for the endpoint

  The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68-1.08]; P=0.20).

  PMID:40884036 · one of two readings recorded this

• symptomatic hypotension and worsening kidney function

  increases, hypotension 3.6% vs 2.2%; worsening kidney function 5.9% vs 4.7%

  The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively.

  PMID:40884036 · one of two readings recorded this

• symptomatic hypotension

  3.6% vs 2.2%

  The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively.

  PMID:40884036 · one of two readings recorded this

• worsening heart failure event

  HR, 0.91 (95% CI, 0.71-1.18)

  A worsening HF event occurred in 115 (9.4%) and 122 (10.3%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.91 [95% CI, 0.71-1.18]).

  PMID:40884036 · both readings recorded this

• worsening kidney function

  5.9% vs 4.7%

  The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively.

  PMID:40884036 · one of two readings recorded this

• diabetic ketoacidosis, dapagliflozin versus control

  no effect, n = 1307

  The IRs (95% confidence interval) of DKA in the PS-matched cohort were 1.54 per 100 person-years (/100 PY; 0.42-3.95) and 1.14/100 PY (0.55-2.10) in the dapagliflozin and control groups, respectively, with a hazard ratio of 1.28 (0.40-4.09)

  PMID:41449745 · one of two readings recorded this

• diabetic ketoacidosis events (composite of DKA resulting in hospitalization and/or death), incidence rate per 100 person-years and hazard ratio, JMDC claims database

  increases, HR 1.28 (0.40-4.09); IR 1.54 vs 1.14 per 100 PY, n = 1307

  Not recorded as a finding: this platform holds no node for the endpoint

  The IRs (95% confidence interval) of DKA in the PS-matched cohort were 1.54 per 100 person-years (/100 PY; 0.42-3.95) and 1.14/100 PY (0.55-2.10) in the dapagliflozin and control groups, respectively, with a hazard ratio of 1.28 (0.40-4.09).

  PMID:41449745 · one of two readings recorded this

• diabetic ketoacidosis events (composite of DKA resulting in hospitalization and/or death), incidence rate per 100 person-years in insulin-treated T1DM, dapagliflozin versus SGLT2i nonusers

  no effect

  Not recorded as a finding: this platform holds no node for the endpoint

  As the confidence intervals overlapped, these results did not suggest any meaningful differences or unexpected higher risk of DKA, consistent with previous reports in other countries.

  PMID:41449745 · one of two readings recorded this

• diabetic ketoacidosis incidence rate (composite of DKA resulting in hospitalization and/or death)

  n = 327

  The IRs (95% confidence interval) of DKA in the PS-matched cohort were 1.54 per 100 person-years (/100 PY; 0.42-3.95) and 1.14/100 PY (0.55-2.10) in the dapagliflozin and control groups, respectively, with a hazard ratio of 1.28 (0.40-4.09)

  PMID:41449745 · one of two readings recorded this

• diabetic ketoacidosis incidence rate (composite of DKA resulting in hospitalization and/or death)

  The IRs in the unmatched cohort were 1.54/100 PY (0.42-3.95) and 0.97/100 PY (0.72-1.27) in the dapagliflozin and control groups, respectively

  PMID:41449745 · one of two readings recorded this

• diabetic ketoacidosis incidence rate (composite of DKA resulting in hospitalization and/or death)

  n = 980

  The IRs (95% confidence interval) of DKA in the PS-matched cohort were 1.54 per 100 person-years (/100 PY; 0.42-3.95) and 1.14/100 PY (0.55-2.10) in the dapagliflozin and control groups, respectively, with a hazard ratio of 1.28 (0.40-4.09)

  PMID:41449745 · one of two readings recorded this

• diabetic ketoacidosis incidence rate (composite of DKA resulting in hospitalization and/or death)

  The IRs in the unmatched cohort were 1.54/100 PY (0.42-3.95) and 0.97/100 PY (0.72-1.27) in the dapagliflozin and control groups, respectively

  PMID:41449745 · one of two readings recorded this

• eGFR

  no effect, p = 0.57

  The eGFR showed no significant difference compared with baseline (76±28 versus 77±29 ml/min per 1.73 m 2 , P = 0.57)

  PMID:41499173 · one of two readings recorded this

• 24-hour urinary protein, g

  decreases, decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90), n = 21

  Not recorded as a finding: no outcome node for 24-hour urinary protein; also a single-arm within-arm change

  After approximately 12 months of follow-up (12.6±1.2 months), the mean 24-hour urinary protein decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90; P < 0.001).

  PMID:41499173 · one of two readings recorded this

• 24-hour urinary protein in patients with Alport syndrome, single-arm before/after

  decreases, decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90), n = 21

  Not recorded as a finding: within-arm change in a single-arm study with no comparator; no outcome node for 24-hour urinary protein (nearest is urinary albumin excretion rate, a different quantity)

  After approximately 12 months of follow-up (12.6±1.2 months), the mean 24-hour urinary protein decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90; P < 0.001).

  PMID:41499173 · one of two readings recorded this

• 24-hour urinary protein

  decreases, p = 0.001

  the mean 24-hour urinary protein decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90; P < 0.001)

  PMID:41499173 · one of two readings recorded this

• eGFR, estimating equation not stated, single-arm change from baseline

  no effect, 76±28 versus 77±29 ml/min per 1.73 m2, p = 0.57, n = 21

  Not recorded as a finding: within-arm before/after change in a single-arm study with no comparator; egfr node needs an equation the abstract never states

  The eGFR showed no significant difference compared with baseline (76±28 versus 77±29 ml/min per 1.73 m 2 , P = 0.57).

  PMID:41499173 · one of two readings recorded this

• eGFR in patients with Alport syndrome, single-arm before/after, equation not stated

  no effect, 76±28 versus 77±29 ml/min per 1.73 m2, p = 0.57, n = 21

  Not recorded as a finding: within-arm change with no comparator; estimating equation not stated, which the egfr node requires

  The eGFR showed no significant difference compared with baseline (76±28 versus 77±29 ml/min per 1.73 m 2 , P = 0.57).

  PMID:41499173 · one of two readings recorded this

• inflammatory cytokine expression in renal cortex

  decreases

  In the animal studies, dapagliflozin significantly reduced macrophage infiltration and the expression of inflammatory cytokines levels in the renal cortex of Col4a3 -mutant mice

  PMID:41499173 · one of two readings recorded this

• macrophage infiltration in renal cortex

  decreases

  In the animal studies, dapagliflozin significantly reduced macrophage infiltration and the expression of inflammatory cytokines levels in the renal cortex of Col4a3 -mutant mice

  PMID:41499173 · one of two readings recorded this

• STING activation and inflammatory cytokine production in mutant tubular epithelial cells

  decreases

  Dapagliflozin effectively inhibited STING activation and suppressed inflammatory cytokines production in mutant TECs

  PMID:41499173 · one of two readings recorded this

• atrial fibrillation prevalence

  n = 1131

  The most frequent comorbidities were atrial fibrillation (46%), type 2 diabetes (37%), and chronic kidney disease (29%).

  PMID:41858299 · one of two readings recorded this

• chronic kidney disease prevalence

  n = 1131

  The most frequent comorbidities were atrial fibrillation (46%), type 2 diabetes (37%), and chronic kidney disease (29%).

  PMID:41858299 · one of two readings recorded this

• ischaemic aetiology

  n = 1131

  Ischaemic aetiology was present in 52% of patients.

  PMID:41858299 · one of two readings recorded this

• left ventricular ejection fraction

  n = 1131

  The mean left ventricular ejection fraction was 32%.

  PMID:41858299 · one of two readings recorded this

• maintenance of dapagliflozin treatment

  n = 1131

  At 6- and 12-month follow-up, maintenance of dapagliflozin treatment was recorded in 95% and 96% of patients, respectively.

  PMID:41858299 · one of two readings recorded this

• maintenance of dapagliflozin treatment

  n = 1131

  At 6- and 12-month follow-up, maintenance of dapagliflozin treatment was recorded in 95% and 96% of patients, respectively.

  PMID:41858299 · one of two readings recorded this

• optimal dose of any RAASi

  n = 1131

  Except for dapagliflozin, which was administered as 10 mg/day, optimal doses were recorded for 14% for any RAASi, 17% for BB, and 25% for MRA.

  PMID:41858299 · one of two readings recorded this

• optimal dose of beta-blocker

  n = 1131

  Except for dapagliflozin, which was administered as 10 mg/day, optimal doses were recorded for 14% for any RAASi, 17% for BB, and 25% for MRA.

  PMID:41858299 · one of two readings recorded this

• optimal dose of MRA

  n = 1131

  Except for dapagliflozin, which was administered as 10 mg/day, optimal doses were recorded for 14% for any RAASi, 17% for BB, and 25% for MRA.

  PMID:41858299 · one of two readings recorded this

• patients receiving all three classes (RAASi, BB, MRA) plus dapagliflozin

  n = 1131

  Of all patients, 60% received concomitantly all three classes plus dapagliflozin for their HFrEF.

  PMID:41858299 · one of two readings recorded this

• patients receiving any combination of RAASi, beta-blocker or MRA at dapagliflozin initiation

  n = 1131

  93% of patients received any combination of a renin-angiotensin-aldosterone system inhibitor (RAASi), beta-blocker (BB), or mineralocorticoid receptor antagonists (MRA)

  PMID:41858299 · one of two readings recorded this

• persistence of dapagliflozin treatment and time to discontinuation in HFrEF, descriptive Kaplan-Meier

  95% and 96% maintained at 6 and 12 months

  Not recorded as a finding: this platform holds no node for the endpoint

  At 6- and 12-month follow-up, maintenance of dapagliflozin treatment was recorded in 95% and 96% of patients, respectively.

  PMID:41858299 · one of two readings recorded this

• type 2 diabetes prevalence

  n = 1131

  The most frequent comorbidities were atrial fibrillation (46%), type 2 diabetes (37%), and chronic kidney disease (29%).

  PMID:41858299 · one of two readings recorded this

• eGFR change

  increases, p = 0.001

  The eGFR was preserved or improved with combination therapy (+2.06% vs -5.08%, P < 0.001)

  PMID:41878680 · one of two readings recorded this

• proportion achieving at least 50% UACR reduction

  increases, p = 0.001

  a higher proportion of patients achieving ≥50% reduction (84.9% vs 45.5%, P < 0.001)

  PMID:41878680 · one of two readings recorded this

• share of eGFR treatment effect mediated by early UACR reduction

  Mediation analysis indicated that early UACR reduction explained only 1.45% of the treatment effect on eGFR changes

  PMID:41878680 · one of two readings recorded this

• UACR reduction and eGFR change over 6 months, finerenone plus dapagliflozin versus dapagliflozin alone, non-diabetic CKD

  eGFR +2.06% with combination vs -5.08% with dapagliflozin alone

  Not recorded as a finding: the comparison was against another active treatment

  The eGFR was preserved or improved with combination therapy (+2.06% vs -5.08%, P < 0.001), whereas dapagliflozin alone therapy was associated with a decline.

  PMID:41878680 · one of two readings recorded this

• UACR reduction and eGFR change over 6 months in non-diabetic CKD, finerenone plus dapagliflozin versus dapagliflozin alone

  eGFR +2.06% with combination versus -5.08% with dapagliflozin alone

  Not recorded as a finding: the comparison was against another active treatment

  The eGFR was preserved or improved with combination therapy (+2.06% vs -5.08%, P < 0.001), whereas dapagliflozin alone therapy was associated with a decline.

  PMID:41878680 · one of two readings recorded this

• UACR reduction, median

  decreases, p = 0.007

  significantly enhanced UACR reduction at 3 months (median 63.4% vs 47.8%, P = 0.007)

  PMID:41878680 · one of two readings recorded this

• UACR reduction, median

  decreases, p = 0.002

  and 6 months (66.9% vs 40.8%, P = 0.002)

  PMID:41878680 · one of two readings recorded this

• 6-minute walk distance

  increases, p = 0.05

  a greater improvement in 6-minute walk distance (P < .05) compared with the 2 monotherapy groups

  PMID:41894290 · one of two readings recorded this

• B-type natriuretic peptide level

  decreases, p = 0.05

  After 24 weeks of intervention, the combination group showed a more significant decrease in B-type natriuretic peptide levels (P < .05)

  PMID:41894290 · one of two readings recorded this

• blood glucose control

  increases, p = 0.05

  the combination group had greater weight loss (P < .05) and better blood glucose control (P < .05)

  PMID:41894290 · one of two readings recorded this

• major cardiovascular composite endpoints incidence

  decreases, p = 0.05

  The incidence of major cardiovascular composite endpoints in the combination group was lower than that in the monotherapy groups (P < .05)

  PMID:41894290 · one of two readings recorded this

• NT-proBNP/BNP, 6-minute walk distance, weight loss, blood glucose and major cardiovascular composite at 24 weeks in obese HFpEF, combination versus each monotherapy

  increases, combination arm showed greater improvement in 6-minute walk distance than the 2 monotherapy groups (P < .05)

  Not recorded as a finding: the intervention held more than the compound

  After 24 weeks of intervention, the combination group showed a more significant decrease in B-type natriuretic peptide levels (P < .05) and a greater improvement in 6-minute walk distance (P < .05) compared with the 2 monotherapy groups.

  PMID:41894290 · one of two readings recorded this

• NT-proBNP/BNP levels, 6-minute walk distance, weight, blood glucose, major cardiovascular composite endpoint at 24 weeks in obese HFpEF; combination vs each monotherapy

  increases, greater improvement in 6-minute walk distance in the combination group than in both monotherapy groups, n = 360

  Not recorded as a finding: the comparison was against another active treatment

  After 24 weeks of intervention, the combination group showed a more significant decrease in B-type natriuretic peptide levels (P < .05) and a greater improvement in 6-minute walk distance (P < .05) compared with the 2 monotherapy groups.

  PMID:41894290 · one of two readings recorded this

• overall incidence of adverse events

  no effect, p = 0.05

  The overall incidence of adverse events was similar among the 3 groups (P > .05)

  PMID:41894290 · one of two readings recorded this

• weight loss

  increases, p = 0.05

  the combination group had greater weight loss (P < .05) and better blood glucose control (P < .05)

  PMID:41894290 · one of two readings recorded this

• albuminuria response (UACR reduction over 30%), logistic regression

  decreases, p = 0.002

  baseline HbA1c (OR = 0.964, 95% CI: 0.941–0.987, p = 0.002)

  PMID:41923691 · one of two readings recorded this

• albuminuria response (UACR reduction over 30%), logistic regression

  decreases, p = 0.004

  baseline SBP (OR = 0.996, 95% CI: 0.993–0.999, p = 0.004)

  PMID:41923691 · one of two readings recorded this

• albuminuria response (UACR reduction over 30%), logistic regression

  no effect, p = 0.001

  baseline UACR (OR = 1.000, 95% CI: 1.000–1.001, p < 0.001)

  PMID:41923691 · one of two readings recorded this

• albuminuria response (UACR reduction over 30%), logistic regression

  decreases, p = 0.001

  the duration of T2DM [odds ratio (OR) = 0.983, 95% CI: 0.975–0.991, p < 0.001]

  PMID:41923691 · one of two readings recorded this

• AUC for discriminating albuminuria response

  0.508 (95% CI: 0.501–0.516)

  PMID:41923691 · one of two readings recorded this

• AUC for discriminating albuminuria response

  0.531 (95% CI: 0.512–0.551)

  PMID:41923691 · one of two readings recorded this

• AUC for discriminating albuminuria response

  0.563 (95% CI: 0.536–0.590)

  PMID:41923691 · one of two readings recorded this

• AUC for discriminating albuminuria response

  The AUC for the combined factors was 0.646 (95% CI: 0.628–0.664)

  PMID:41923691 · one of two readings recorded this

• AUC for discriminating albuminuria response

  0.603 (95% CI: 0.591–0.615)

  PMID:41923691 · one of two readings recorded this

• UACR improvement rate, linear regression

  decreases, p = 0.004

  baseline HbA1c level (β = −0.009, 95% CI: −0.015 to −0.003, p = 0.004)

  PMID:41923691 · one of two readings recorded this

• UACR improvement rate, linear regression

  decreases, p = 0.001

  baseline SBP level (β = −0.002, 95% CI: −0.003 to −0.001, p < 0.001)

  PMID:41923691 · one of two readings recorded this

• UACR improvement rate, linear regression

  no effect, p = 0.001

  baseline UACR level (β = 0.000, 95% CI: 0.000–0.000, p < 0.001)

  PMID:41923691 · one of two readings recorded this

• UACR improvement rate, linear regression

  decreases, p = 0.001

  the duration of T2DM (β = −0.005, 95% CI: −0.007 to −0.003, p < 0.001)

  PMID:41923691 · one of two readings recorded this

• UACR improvement rate

  decreases

  Patients with eGFR of 60–89 mL/min/1.73 m² showed the greatest reduction in UACR after treatment (42.12% ± 34.73%)

  PMID:41923691 · one of two readings recorded this

• UACR improvement rate

  decreases

  patients with eGFR < 60 mL/min/1.73 m² exhibited the smallest improvement (16.36% ± 9.82%)

  PMID:41923691 · one of two readings recorded this

• UACR improvement rate

  decreases

  followed by those with eGFR ≥ 90 mL/min/1.73 m² (29.87% ± 18.14%)

  PMID:41923691 · one of two readings recorded this

• UACR non-responders (improvement 30% or less)

  no effect, n = 10860

  6,373 patients (58.68%) exhibiting a UACR improvement rate of over 30% after treatment were classified as responders, while the remaining 4,487 patients (41.32%) were classified as non-responders

  PMID:41923691 · one of two readings recorded this

• UACR responders (improvement over 30%)

  decreases, n = 10860

  6,373 patients (58.68%) exhibiting a UACR improvement rate of over 30% after treatment were classified as responders, while the remaining 4,487 patients (41.32%) were classified as non-responders

  PMID:41923691 · one of two readings recorded this

• urinary albumin-creatinine ratio (UACR) change after 3 months of dapagliflozin 10 mg/day, responder (>30% reduction) classification, type 2 diabetic kidney disease, single-arm real-world cohort

  decreases, n = 10860

  Not recorded as a finding: this platform holds no node for the endpoint

  Analysis of UACR improvement showed an overall trend of decreasing UACR after dapagliflozin treatment compared to baseline, but the response to dapagliflozin varied significantly among individuals.

  PMID:41923691 · one of two readings recorded this

• urinary albumin-creatinine ratio (UACR) change after 3 months of dapagliflozin 10 mg/day, responder defined as UACR reduction over 30%, single uncontrolled retrospective cohort

  decreases

  Not recorded as a finding: this platform holds no node for the endpoint

  Analysis of UACR improvement showed an overall trend of decreasing UACR after dapagliflozin treatment compared to baseline, but the response to dapagliflozin varied significantly among individuals.

  PMID:41923691 · one of two readings recorded this

• all-cause mortality

  decreases, RR = 0.67, p = 0.02

  Within this analysis, dapagliflozin was associated with significantly lower mortality (RR = 0.67; p = 0.02) but showed no significant difference for cardiovascular (RR = 0.77; p = 0.15) or genitourinary events (RR = 0.98; p = 0.97).

  PMID:42021630 · one of two readings recorded this

• hemoglobin

  increases, MD = 4.37 g/L; 95% CI 0.71–8.03 g/L; p = 0.02, p = 0.02, n = 4227

  The quantitative analysis of four studies (n = 4,227) demonstrated that dapagliflozin significantly increased hemoglobin levels compared with placebo (MD = 4.37 g/L; 95% CI 0.71–8.03 g/L; p = 0.02; I2 = 100%).

  PMID:42021630 · both readings recorded this

• all-cause mortality (adverse-event subgroup)

  decreases, RR = 0.67; p = 0.02, p = 0.02

  Within this analysis, dapagliflozin was associated with significantly lower mortality (RR = 0.67; p = 0.02) but showed no significant difference for cardiovascular (RR = 0.77; p = 0.15) or genitourinary events (RR = 0.98; p = 0.97).

  PMID:42021630 · one of two readings recorded this

• all-cause mortality, cardiovascular events and genitourinary events, adverse-event subgroup analysis

  decreases, mortality RR = 0.67; p = 0.02; cardiovascular RR = 0.77; p = 0.15; genitourinary RR = 0.98; p = 0.97, p = 0.02

  Not recorded as a finding: mortality maps to CAT:outcome/all-cause-mortality, which records the follow-up horizon with each finding as not optional; this sentence states no horizon, so the finding is not extractable as a claim

  Within this analysis, dapagliflozin was associated with significantly lower mortality (RR = 0.67; p = 0.02) but showed no significant difference for cardiovascular (RR = 0.77; p = 0.15) or genitourinary events (RR = 0.98; p = 0.97).

  PMID:42021630 · one of two readings recorded this

• cardiovascular events (adverse-event subgroup)

  no effect, RR = 0.77; p = 0.15, p = 0.15

  Within this analysis, dapagliflozin was associated with significantly lower mortality (RR = 0.67; p = 0.02) but showed no significant difference for cardiovascular (RR = 0.77; p = 0.15) or genitourinary events (RR = 0.98; p = 0.97).

  PMID:42021630 · one of two readings recorded this

• genitourinary events (adverse-event subgroup)

  no effect, RR = 0.98; p = 0.97, p = 0.97

  Within this analysis, dapagliflozin was associated with significantly lower mortality (RR = 0.67; p = 0.02) but showed no significant difference for cardiovascular (RR = 0.77; p = 0.15) or genitourinary events (RR = 0.98; p = 0.97).

  PMID:42021630 · one of two readings recorded this

• hematocrit, sensitivity analysis excluding one cross-sectional study

  increases, MD = 2.15; 95% CI = 1.86-2.44, n = 3423

  Not recorded as a finding: sensitivity/secondary analysis result; the overall pooled result across all three studies (no_effect) was recorded as the claim instead

  However, after a sensitivity analysis excluded one cross-sectional study, the remaining two studies (n = 3,423) showed a highly significant increase in hematocrit (MD = 2.15; 95% CI = 1.86–2.44; p < 0.00001; I2 = 100%).

  PMID:42021630 · both readings recorded this

• overall adverse event risk (composite of mortality, cardiovascular and genitourinary events)

  RR = 0.78; 95% CI = 0.59-1.02, p = 0.07

  The primary analysis of adverse events, which pooled three and two studies in three subgroup analyses, showed a non-significant reduction in the overall risk (RR = 0.78; 95% CI = 0.59–1.02; p = 0.07; I2 = 49%).

  PMID:42021630 · one of two readings recorded this

• overall adverse-event risk

  no effect, RR = 0.78; 95% CI = 0.59–1.02; p = 0.07, p = 0.07

  The primary analysis of adverse events, which pooled three and two studies in three subgroup analyses, showed a non-significant reduction in the overall risk (RR = 0.78; 95% CI = 0.59–1.02; p = 0.07; I2 = 49%).

  PMID:42021630 · one of two readings recorded this

• eGFR

  decreases, p = 0.001

  eGFR, mL/min/1.73 m2 | 93.33±13.81 | 93.12±14.10 | 52.95±27.18**,a | <0.001

  PMID:42030222 · one of two readings recorded this

• age

  increases, p = 0.001

  Age, years | 54.18±11.90 | 57.61±9.98** | 64.02±12.48**,a | <0.001

  PMID:42030222 · one of two readings recorded this

• albuminuria

  decreases, p = 0.033

  accompanied by lower lactate dehydrogenase (p = 0.011) and albuminuria (p = 0.033)

  PMID:42030222 · one of two readings recorded this

• albuminuria

  increases, p = 0.001

  Albuminuria, mg/24 h | 5.98 [2.26, 10.89] | 6.05 [4.06, 10.80] | 302.00 [90.21, 771.08]**,a | <0.001

  PMID:42030222 · one of two readings recorded this

• blood glucose in db/db mice

  decreases

  Dapagliflozin treatment markedly reduced blood glucose, urinary albumin to creatinine ratio (UACR), and renal cortical lactate levels in a dose-dependent manner

  PMID:42030222 · one of two readings recorded this

• correlation of plasma lactate with albuminuria

  increases, p = 0.008

  plasma lactate was positively associated with serum creatinine (r = 0.185, p = 0.016) and albuminuria (r = 0.203, p = 0.008)

  PMID:42030222 · one of two readings recorded this

• correlation of plasma lactate with serum creatinine

  increases, p = 0.016

  plasma lactate was positively associated with serum creatinine (r = 0.185, p = 0.016) and albuminuria (r = 0.203, p = 0.008)

  PMID:42030222 · one of two readings recorded this

• glomerular basement membrane thickness

  decreases

  Ultrastructural analysis further demonstrated that dapagliflozin significantly ameliorated hyperglycemia-induced GBM thickening and podocyte foot process effacement

  PMID:42030222 · one of two readings recorded this

• HbA1c

  increases, p = 0.001

  HbA1c, % | 5.54 [5.38, 5.82] | 8.07 [6.74, 9.82]** | 8.50 [7.12, 10.01]** | <0.001

  PMID:42030222 · one of two readings recorded this

• hyperlactatemia, multivariate logistic regression, SGLT2i use

  decreases, p = 0.034

  SGLT2i use | 0.258 (0.075, 0.890) | 0.032 | 0.132 (0.020, 0.856) | 0.034

  PMID:42030222 · one of two readings recorded this

• hyperlactatemia, multivariate logistic regression, WBC count

  increases, p = 0.03

  WBC, 109/L | 1.342 (1.009, 1.785) | 0.044 | 1.652 (1.051, 2.595) | 0.030

  PMID:42030222 · one of two readings recorded this

• hyperlactatemia, univariate logistic regression, SGLT2i use

  decreases, p = 0.032

  SGLT2i use | 0.258 (0.075, 0.890) | 0.032 | 0.132 (0.020, 0.856) | 0.034

  PMID:42030222 · one of two readings recorded this

• incidence of hyperlactatemia

  decreases, p = 0.041

  patients treated with SGLT2 inhibitors exhibited a significantly lower incidence of hyperlactatemia (40.0% vs. 16.0%, p = 0.041)

  PMID:42030222 · one of two readings recorded this

• lactate dehydrogenase

  decreases, p = 0.011

  accompanied by lower lactate dehydrogenase (p = 0.011) and albuminuria (p = 0.033)

  PMID:42030222 · one of two readings recorded this

• lactate dehydrogenase

  increases, p = 0.001

  LDH, U/L | 164.7 [154.7, 185.0] | 175.2 [155.4, 195.8] | 193.0 [168.6, 226.6]**,a | <0.001

  PMID:42030222 · one of two readings recorded this

• mesangial expansion (PAS staining)

  decreases

  PAS staining showed pronounced mesangial expansion in db/db glomeruli compared with db/m controls, which was substantially attenuated by dapagliflozin

  PMID:42030222 · one of two readings recorded this

• nuclear H4K12la expression

  decreases

  Dapagliflozin treatment significantly reversed the high glucose-induced increase in nuclear H4K12la expression

  PMID:42030222 · one of two readings recorded this

• plasma lactate in DKD patients on SGLT2 inhibitors versus not, retrospective, mmol/L

  decreases, 2.07 ± 0.73 vs. 1.60 ± 0.55 mmol/L, p = 0.008

  Not recorded as a finding: no outcome node for plasma lactate; exposure is the SGLT2 inhibitor class, not dapagliflozin specifically; observational

  Consistently, plasma lactate levels were reduced in the SGLT2 group (2.07 ± 0.73 vs. 1.60 ± 0.55 mmol/L, p = 0.008), accompanied by lower lactate dehydrogenase (p = 0.011) and albuminuria (p = 0.033).

  PMID:42030222 · one of two readings recorded this

• plasma lactate in DKD patients, SGLT2 inhibitor users versus non-users

  decreases, 2.07 ± 0.73 vs. 1.60 ± 0.55 mmol/L, p = 0.008

  Not recorded as a finding: exposure is the SGLT2 inhibitor class, not dapagliflozin specifically, and the comparison is retrospective and non-randomised; no plasma lactate outcome node

  Consistently, plasma lactate levels were reduced in the SGLT2 group (2.07 ± 0.73 vs. 1.60 ± 0.55 mmol/L, p = 0.008), accompanied by lower lactate dehydrogenase (p = 0.011) and albuminuria (p = 0.033).

  PMID:42030222 · one of two readings recorded this

• plasma lactate

  decreases, p = 0.008

  plasma lactate levels were reduced in the SGLT2 group (2.07 ± 0.73 vs. 1.60 ± 0.55 mmol/L, p = 0.008)

  PMID:42030222 · one of two readings recorded this

• plasma lactate

  increases, p = 0.001

  Plasma lactate, mmol/L | 1.44 [1.24, 1.70] | 1.88 [1.45, 2.33]** | 1.91 [1.53, 2.38]**,a | <0.001

  PMID:42030222 · one of two readings recorded this

• podocin and synaptopodin expression in high-glucose podocytes

  increases

  the expression of podocyte-specific markers, podocin and synaptopodin, was markedly restored following either dapagliflozin treatment or siLDHA transfection compared with the untreated high-glucose group

  PMID:42030222 · one of two readings recorded this

• podocin and synaptopodin expression

  increases

  the expression of podocyte-specific markers, podocin and synaptopodin, was markedly restored following dapagliflozin treatment compared with untreated db/db mice

  PMID:42030222 · one of two readings recorded this

• podocyte foot process effacement

  decreases

  Ultrastructural analysis further demonstrated that dapagliflozin significantly ameliorated hyperglycemia-induced GBM thickening and podocyte foot process effacement

  PMID:42030222 · one of two readings recorded this

• renal cortical lactate in db/db mice

  decreases

  Dapagliflozin treatment markedly reduced blood glucose, urinary albumin to creatinine ratio (UACR), and renal cortical lactate levels in a dose-dependent manner

  PMID:42030222 · one of two readings recorded this

• serum creatinine

  increases, p = 0.001

  SCr, µmol/L | 69.7 [63.7, 76.3] | 69.4 [61.4, 78.1] | 108.2 [84.8, 149.9]**,a | <0.001

  PMID:42030222 · one of two readings recorded this

• urinary albumin-to-creatinine ratio (ELISA, spot/metabolic cage) in db/db mice

  decreases, dose-dependent reduction

  Not recorded as a finding: no outcome node for UACR in mice; urinary-albumin-excretion-rate node requires a timed collection in ug/min

  Dapagliflozin treatment markedly reduced blood glucose, urinary albumin to creatinine ratio (UACR), and renal cortical lactate levels in a dose-dependent manner.

  PMID:42030222 · one of two readings recorded this

• urinary albumin to creatinine ratio in db/db mice

  decreases

  Dapagliflozin treatment markedly reduced blood glucose, urinary albumin to creatinine ratio (UACR), and renal cortical lactate levels in a dose-dependent manner

  PMID:42030222 · one of two readings recorded this

• urinary albumin to creatinine ratio (UACR) by ELISA, db/db mice

  decreases

  Not recorded as a finding: no outcome node for rodent UACR; urinary-albumin-excretion-rate requires a timed collection in ug/min, and the sentence also bundles blood glucose and renal lactate

  Dapagliflozin treatment markedly reduced blood glucose, urinary albumin to creatinine ratio (UACR), and renal cortical lactate levels in a dose-dependent manner.

  PMID:42030222 · one of two readings recorded this

• urine protein

  increases, p = 0.001

  Urine protein, g/24 h | 0.08 [0.06, 0.11] | 0.08 [0.06, 0.10] | 0.52 [0.21, 1.38]**,a | <0.001

  PMID:42030222 · one of two readings recorded this

• eGFR

  increases, p = 0.004

  estimated glomerular filtration rate (eGFR) increased significantly in both groups, with the Combination Therapy Group showing a more pronounced improvement (t = 2.898, P =0.004)

  PMID:42109733 · one of two readings recorded this

• 2hPG after treatment

  decreases, p = 0.001

  After treatment | 11.24 ± 1.84 | 9.71 ± 1.68 | 6.200 | < 0.001

  PMID:42109733 · one of two readings recorded this

• 2hPG before treatment

  no effect, p = 0.824

  Before treatment | 13.47 ± 2.16 | 13.54 ± 2.11 | 0.222 | 0.824

  PMID:42109733 · one of two readings recorded this

• blood urea nitrogen (BUN)

  decreases, p = 0.001

  with the combination therapy yielding a more substantial decrease (t =3.226, P= 0.001)

  PMID:42109733 · one of two readings recorded this

• blood urea nitrogen, enzymatic assay, mmol/L

  decreases, t = 3.226, p = 0.001

  Not recorded as a finding: reported in mmol/L without stating the nitrogen scale the BUN node requires

  Blood urea nitrogen (BUN) levels also declined significantly across both groups, with the combination therapy yielding a more substantial decrease (t =3.226, P= 0.001).

  PMID:42109733 · one of two readings recorded this

• C-IV after treatment

  decreases, p = 0.01

  After treatment | 59.12 ± 10.27 | 55.38 ± 10.19 | 2.612 | 0.010

  PMID:42109733 · one of two readings recorded this

• C-IV before treatment

  no effect, p = 0.958

  Before treatment | 70.31 ± 10.26 | 70.38 ± 10.88 | 0.052 | 0.958

  PMID:42109733 · one of two readings recorded this

• DBP after treatment

  decreases, p = 0.001

  After treatment | 86.29 ± 4.79 | 83.12 ± 4.58 | 4.830 | < 0.001

  PMID:42109733 · one of two readings recorded this

• DBP before treatment

  no effect, p = 0.527

  Before treatment | 93.52 ± 5.66 | 94.03 ± 5.81 | 0.634 | 0.527

  PMID:42109733 · one of two readings recorded this

• effective clinical outcome, adjusted (multivariate logistic regression)

  increases, p = 0.004

  combination therapy remained independently associated with a higher likelihood of achieving an effective clinical outcome after adjusting for these covariates (OR = 2.417, 95% CI: 1.315–4.443, P = 0.004)

  PMID:42109733 · one of two readings recorded this

• FPG after treatment

  decreases, p = 0.001

  After treatment | 7.58 ± 1.10 | 6.79 ± 1.02 | 5.302 | < 0.001

  PMID:42109733 · one of two readings recorded this

• FPG before treatment

  no effect, p = 0.502

  Before treatment | 8.92 ± 1.35 | 9.04 ± 1.29 | 0.673 | 0.502

  PMID:42109733 · one of two readings recorded this

• GluCV after treatment

  decreases, p = 0.001

  After treatment | 24.09 ± 3.79 | 21.01 ± 3.42 | 6.087 | < 0.001

  PMID:42109733 · one of two readings recorded this

• GluCV before treatment

  no effect, p = 0.584

  Before treatment | 28.34 ± 4.17 | 28.02 ± 4.31 | 0.549 | 0.584

  PMID:42109733 · one of two readings recorded this

• hs-CRP after treatment

  decreases, p = 0.001

  After treatment | 3.68 ± 1.04 | 3.16 ± 1.06 | 3.539 | < 0.001

  PMID:42109733 · one of two readings recorded this

• hs-CRP before treatment

  no effect, p = 0.826

  Before treatment | 4.32 ± 1.28 | 4.39 ± 1.22 | 0.220 | 0.826

  PMID:42109733 · one of two readings recorded this

• IL-33 after treatment

  decreases, p = 0.003

  After treatment | 0.79 ± 0.18 | 0.71 ± 0.19 | 3.030 | 0.003

  PMID:42109733 · one of two readings recorded this

• IL-33 before treatment

  no effect, p = 0.48

  Before treatment | 0.86 ± 0.23 | 0.84 ± 0.22 | 0.708 | 0.480

  PMID:42109733 · one of two readings recorded this

• IL-6 after treatment

  decreases, p = 0.011

  After treatment | 6.79 ± 1.83 | 6.14 ± 1.82 | 2.552 | 0.011

  PMID:42109733 · one of two readings recorded this

• IL-6 before treatment

  no effect, p = 0.831

  Before treatment | 7.53 ± 2.14 | 7.59 ± 2.09 | 0.214 | 0.831

  PMID:42109733 · one of two readings recorded this

• IVSd

  decreases, p = 0.003

  IVSd: t = 3.055, P= 0.003

  PMID:42109733 · one of two readings recorded this

• LAD

  decreases, p = 0.005

  LAD: t = 2.869, P = 0.005

  PMID:42109733 · one of two readings recorded this

• LAGE after treatment

  decreases, p = 0.001

  After treatment | 6.44 ± 1.21 | 5.59 ± 1.09 | 5.253 | < 0.001

  PMID:42109733 · one of two readings recorded this

• LAGE before treatment

  no effect, p = 0.656

  Before treatment | 7.56 ± 1.43 | 7.47 ± 1.39 | 0.446 | 0.656

  PMID:42109733 · one of two readings recorded this

• left ventricular ejection fraction by biplane Simpson echocardiography

  increases, 60.12 vs 56.75 percent after treatment

  Not recorded as a finding: the LVEF node is for modality-unspecified measurements and this paper states echocardiography

  Left ventricular ejection fraction (LVEF) improved in both groups, with the Combination Therapy Group demonstrating a greater enhancement (Monotherapy: 54.28 ± 5.14% → 56.75 ± 4.96%; Combination: 53.91 ± 5.37% → 60.12 ± 4.68%; t = 4.992, P< 0.001).

  PMID:42109733 · both readings recorded this

• LN after treatment

  decreases, p = 0.001

  After treatment | 10.42 ± 2.34 | 9.29 ± 2.19 | 3.573 | < 0.001

  PMID:42109733 · one of two readings recorded this

• LN before treatment

  no effect, p = 0.72

  Before treatment | 15.48 ± 3.49 | 15.31 ± 3.27 | 0.358 | 0.720

  PMID:42109733 · one of two readings recorded this

• LVEDD

  decreases, p = 0.001

  LVEDD: t = 3.960, P< 0.001

  PMID:42109733 · one of two readings recorded this

• LVEF

  increases, p = 0.001

  Monotherapy: 54.28 ± 5.14% → 56.75 ± 4.96%; Combination: 53.91 ± 5.37% → 60.12 ± 4.68%; t = 4.992, P< 0.001

  PMID:42109733 · one of two readings recorded this

• LVESD

  decreases, p = 0.002

  LVESD: t = 3.064, P = 0.002

  PMID:42109733 · one of two readings recorded this

• MAGE after treatment

  decreases, p = 0.001

  After treatment | 4.09 ± 0.83 | 3.49 ± 0.79 | 5.360 | < 0.001

  PMID:42109733 · one of two readings recorded this

• MAGE before treatment

  no effect, p = 0.531

  Before treatment | 4.82 ± 0.96 | 4.74 ± 0.93 | 0.628 | 0.531

  PMID:42109733 · one of two readings recorded this

• MAP after treatment

  decreases, p = 0.001

  After treatment | 104.09 ± 4.88 | 100.18 ± 4.69 | 5.828 | < 0.001

  PMID:42109733 · one of two readings recorded this

• MAP before treatment

  no effect, p = 0.513

  Before treatment | 113.13 ± 5.86 | 113.68 ± 6.14 | 0.655 | 0.513

  PMID:42109733 · one of two readings recorded this

• markedly effective proportion

  increases

  a higher proportion of patients in the combination regimen were classified as “markedly effective” (50.98% vs. 32.35%)

  PMID:42109733 · one of two readings recorded this

• NT-proBNP

  decreases, p = 0.013

  Serum NT-proBNP concentrations also declined in both groups, with the Combination Therapy Group showing a larger decrease (t = 2.508, P = 0.013)

  PMID:42109733 · one of two readings recorded this

• PGE after treatment

  decreases, p = 0.001

  After treatment | 4.89 ± 0.96 | 4.11 ± 0.86 | 6.139 | < 0.001

  PMID:42109733 · one of two readings recorded this

• PGE before treatment

  no effect, p = 0.643

  Before treatment | 5.73 ± 1.12 | 5.66 ± 1.08 | 0.464 | 0.643

  PMID:42109733 · one of two readings recorded this

• PIIINP after treatment

  decreases, p = 0.003

  After treatment | 42.25 ± 7.48 | 39.14 ± 7.42 | 2.984 | 0.003

  PMID:42109733 · one of two readings recorded this

• PIIINP before treatment

  no effect, p = 0.567

  Before treatment | 49.48 ± 10.63 | 48.62 ± 10.72 | 0.573 | 0.567

  PMID:42109733 · one of two readings recorded this

• SBP after treatment

  decreases, p = 0.001

  After treatment | 139.68 ± 6.82 | 134.86 ± 6.37 | 5.216 | < 0.001

  PMID:42109733 · one of two readings recorded this

• SBP before treatment

  no effect, p = 0.609

  Before treatment | 152.36 ± 8.46 | 152.98 ± 8.82 | 0.512 | 0.609

  PMID:42109733 · one of two readings recorded this

• serum creatinine (SCr)

  decreases, p = 0.018

  SCr: t = 2.390, P = 0.018

  PMID:42109733 · one of two readings recorded this

• sICAM-1 after treatment

  no effect, p = 0.108

  After treatment | 286.25 ± 43.41 | 276.59 ± 42.07 | 1.613 | 0.108

  PMID:42109733 · one of two readings recorded this

• sICAM-1 before treatment

  no effect, p = 0.728

  Before treatment | 311.46 ± 48.27 | 309.12 ± 47.86 | 0.348 | 0.728

  PMID:42109733 · one of two readings recorded this

• soluble ICAM-1, ELISA

  no effect, p = 0.108

  Not recorded as a finding: no outcome node for sICAM-1

  In contrast, changes in sICAM-1 did not differ significantly between the groups (P = 0.108).

  PMID:42109733 · one of two readings recorded this

• sST2 after treatment

  decreases, p = 0.003

  After treatment | 26.58 ± 5.12 | 24.42 ± 5.31 | 2.956 | 0.003

  PMID:42109733 · one of two readings recorded this

• sST2 before treatment

  no effect, p = 0.537

  Before treatment | 28.47 ± 6.39 | 29.03 ± 6.48 | 0.619 | 0.537

  PMID:42109733 · one of two readings recorded this

• systolic, diastolic and mean arterial blood pressure at 24 weeks, protocol not recorded

  decreases

  Not recorded as a finding: the only sentence reporting the between-arm difference refers to 'these parameters' and does not name SBP, DBP or MAP, so no object span; the sentence naming dapagliflozin is hedged ('may enhance')

  Notably, the reductions in these parameters were significantly more pronounced in the Combination Therapy Group compared with the Monotherapy Group (all P < 0.001; Table 2).

  PMID:42109733 · one of two readings recorded this

• systolic, diastolic blood pressure and mean arterial pressure after 24 weeks, acquisition protocol not described

  decreases, p = 0.001

  Not recorded as a finding: the only prose sentence names these as 'these parameters' without naming SBP or DBP, so no object span is available in the quote

  Notably, the reductions in these parameters were significantly more pronounced in the Combination Therapy Group compared with the Monotherapy Group (all P < 0.001; Table 2).

  PMID:42109733 · one of two readings recorded this

• TGF-β1 after treatment

  decreases, p = 0.001

  After treatment | 29.97 ± 3.58 | 27.13 ± 3.74 | 5.528 | < 0.001

  PMID:42109733 · one of two readings recorded this

• TGF-β1 before treatment

  no effect, p = 0.407

  Before treatment | 32.48 ± 4.19 | 32.97 ± 4.12 | 0.831 | 0.407

  PMID:42109733 · one of two readings recorded this

• TNF-α after treatment

  decreases, p = 0.003

  After treatment | 16.93 ± 3.52 | 15.38 ± 3.74 | 3.053 | 0.003

  PMID:42109733 · one of two readings recorded this

• TNF-α before treatment

  no effect, p = 0.753

  Before treatment | 18.76 ± 4.23 | 18.94 ± 4.17 | 0.315 | 0.753

  PMID:42109733 · one of two readings recorded this

• total effective rate (composite clinical efficacy)

  increases, p = 0.018

  The total effective rate was significantly greater in the Combination Therapy Group (88.24%) compared with the Monotherapy Group (75.49%, P = 0.018)

  PMID:42109733 · one of two readings recorded this

• UACR

  decreases, p = 0.006

  UACR: t =2.781, P = 0.006

  PMID:42109733 · one of two readings recorded this

• urinary albumin-to-creatinine ratio, first-morning spot urine, immunoturbidimetric

  decreases, greater reduction in the combination arm, t = 2.781, p = 0.006

  Not recorded as a finding: urinary-albumin-excretion-rate node requires a timed collection in ug/min; a spot UACR is a different quantity

  Urinary albumin-to-creatinine ratio (UACR) and serum creatinine (SCr) both decreased in both cohorts, with greater reductions observed in the combination regimen (UACR: t =2.781, P = 0.006; SCr: t = 2.390, P = 0.018).

  PMID:42109733 · one of two readings recorded this

• urinary albumin-to-creatinine ratio on first-morning spot urine

  decreases, t = 2.781, p = 0.006

  Not recorded as a finding: no outcome node for UACR; the urinary albumin excretion rate node requires a timed collection in ug/min

  Urinary albumin-to-creatinine ratio (UACR) and serum creatinine (SCr) both decreased in both cohorts, with greater reductions observed in the combination regimen (UACR: t =2.781, P = 0.006; SCr: t = 2.390, P = 0.018).

  PMID:42109733 · one of two readings recorded this

• heart rate variability indices (SDNN, SDANN, RMSSD, pNN50, lnHF)

  decreases, n = 22

  After 12 weeks of GLP-1 RA therapy, the Control group showed significant reductions in SDNN, SDANN, RMSSD, pNN50, and lnHF, together with increases in lnLF and the lnLF/lnHF ratio

  PMID:42199788 · one of two readings recorded this

• heart rate variability indices

  no effect, n = 23

  whereas no significant within-group changes in HRV indices were observed in the DAPA group

  PMID:42199788 · one of two readings recorded this

• lnLF and lnLF/lnHF ratio

  increases, n = 22

  After 12 weeks of GLP-1 RA therapy, the Control group showed significant reductions in SDNN, SDANN, RMSSD, pNN50, and lnHF, together with increases in lnLF and the lnLF/lnHF ratio

  PMID:42199788 · one of two readings recorded this

• SDNN, SDANN, lnHF and lnLF/lnHF ratio, adjusted between-group difference

  unclear

  After covariate adjustment, significant between-group differences remained for SDNN, SDANN, lnHF, and the lnLF/lnHF ratio

  PMID:42199788 · one of two readings recorded this

• triglycerides

  decreases

  lipids (triglycerides to 0.72 mmol/L), liver enzymes (ALT to 9.74 U/L), and UACR (to 7.36 mg/g)

  PMID:42199793 · one of two readings recorded this

• alanine aminotransferase (ALT)

  decreases

  lipids (triglycerides to 0.72 mmol/L), liver enzymes (ALT to 9.74 U/L), and UACR (to 7.36 mg/g)

  PMID:42199793 · one of two readings recorded this

• change in time in range (regression)

  increases, p = 0.001

  combination therapy predicted greatest TIR change (β=7.896, P<0.001)

  PMID:42199793 · one of two readings recorded this

• estimated glomerular filtration rate (eGFR)

  increases, p = 0.05

  higher eGFR (to 122.41 mL/min/1.73m²; all P<0.05 vs. others)

  PMID:42199793 · one of two readings recorded this

• HbA1c

  decreases

  greater reductions in HbA1c (to 5.52%), fasting glucose, blood pressure (systolic to 124 mmHg)

  PMID:42199793 · one of two readings recorded this

• systolic blood pressure

  decreases

  greater reductions in HbA1c (to 5.52%), fasting glucose, blood pressure (systolic to 124 mmHg)

  PMID:42199793 · one of two readings recorded this

• time in range by continuous glucose monitoring, HbA1c, fasting glucose, blood pressure, triglycerides, ALT, UACR and eGFR at 12 weeks

  increases, combination therapy predicted greatest TIR change (beta 7.896)

  Not recorded as a finding: the intervention held more than the compound

  TIR correlated with improved hepatorenal markers; combination therapy predicted greatest TIR change (β=7.896, P<0.001).

  PMID:42199793 · one of two readings recorded this

• time in range (continuous glucose monitoring)

  increases, p = 0.001

  Combination therapy achieved superior TIR (94.86 ± 3.65% vs. ~80% in monotherapies and 81.44% in control; P<0.001)

  PMID:42199793 · one of two readings recorded this

• urinary albumin-to-creatinine ratio (UACR)

  decreases

  lipids (triglycerides to 0.72 mmol/L), liver enzymes (ALT to 9.74 U/L), and UACR (to 7.36 mg/g)

  PMID:42199793 · one of two readings recorded this

• dapagliflozin discontinuations per 100 patient-years and proportion of patients on guideline-directed medical therapy, HFrEF, Baltic cohort

  13.2 per 100 patient-years (95% CI 8.2-18.2)

  Not recorded as a finding: this platform holds no node for the endpoint

  The number of dapagliflozin discontinuations per 100 patient-years was found to be 13.2 (95% CI 8.2-18.2).

  PMID:42512852 · one of two readings recorded this

• dapagliflozin discontinuations per 100 patient-years

  n = 178

  The number of dapagliflozin discontinuations per 100 patient-years was found to be 13.2 (95% CI 8.2-18.2)

  PMID:42512852 · one of two readings recorded this

The whole record — 210 rows